A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

NCT01179594 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped This study was canceled for operational reasons.

Conditions

Hepatitis B, Chronic

Interventions

DRUG: entecavir
DRUG: peginterferon alfa-2a [Pegasys]
DRUG: peginterferon alfa-2a [Pegasys]
DRUG: placebo

Sponsor

Hoffmann-La Roche